Clinical Trial Update: A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

View source ↗

Summary

Pfizer is conducting a post-market study to learn about NURTEC ODT 75 mg (rimegepant) in Korea. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• NURTEC ODT 75 mg (rimegepant)

Snippet

Sponsor: Pfizer | Conditions: Migraine With or Without Aura | Status: NOT_YET_RECRUITING